Status and prospect of CAR-T cell therapy for prostate cancer / 中华泌尿外科杂志
Chinese Journal of Urology
;
(12): 877-880, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-993939
ABSTRACT
At present, the treatment of advanced tumors has entered the immune era, and immune checkpoint inhibitors have shown good efficacy in prostate cancer. Cellular immunotherapy such as CAR-T therapy (chimeric antigen receptor T-cell immunotherapy) has shown excellent results in hematological and digestive system malignancies, but its efficacy in urinary system tumors is not yet clear. This review will explain the current status and application prospects of CAR-T in the treatment of prostate cancer, including target selection, predicament, and function enhancement strategies of CAR molecules in prostate cancer, aiming to open up new perspectives for cellular immunotherapy of prostate cancer and ideas.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Urology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS